Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1270. doi: 10.1074/mcp.W119.001571. No abstract available.

PMID:
31154440
2.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Straten PT, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1255-1268. doi: 10.1074/mcp.RA119.001524.

PMID:
31154438
3.

Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients.

Boydell E, Marinari E, Migliorini D, Dietrich PY, Patrikidou A, Dutoit V.

Cancers (Basel). 2019 Apr 2;11(4). pii: E464. doi: 10.3390/cancers11040464.

4.

Peptides as cancer vaccines.

Calvo Tardón M, Allard M, Dutoit V, Dietrich PY, Walker PR.

Curr Opin Pharmacol. 2019 Mar 1;47:20-26. doi: 10.1016/j.coph.2019.01.007. [Epub ahead of print] Review.

PMID:
30831470
5.

Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.

Migliorini D, Dutoit V, Allard M, Hallez NG, Marinari E, Widmer V, Philippin G, Corlazzoli F, Gustave R, Kreutzfeldt M, Blazek N, Wasem J, Hottinger A, Koka A, Momjian S, Lobrinus A, Merkler D, Vargas MI, Walker PR, Patrikidou A, Dietrich PY.

Neuro Oncol. 2019 Feb 12. doi: 10.1093/neuonc/noz040. [Epub ahead of print]

PMID:
30753611
6.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z.

PMID:
30733620
7.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
8.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2018 Nov;17(11):2132-2145. doi: 10.1074/mcp.RA118.000792. Epub 2018 Aug 2. Retraction in: Mol Cell Proteomics. 2019 Jun;18(6):1270.

PMID:
30072578
9.

Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.

Dutoit V, Migliorini D, Ranzanici G, Marinari E, Widmer V, Lobrinus JA, Momjian S, Costello J, Walker PR, Okada H, Weinschenk T, Herold-Mende C, Dietrich PY.

Oncoimmunology. 2017 Nov 7;7(2):e1391972. doi: 10.1080/2162402X.2017.1391972. eCollection 2018.

10.

Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma.

Cosset É, Ilmjärv S, Dutoit V, Elliott K, von Schalscha T, Camargo MF, Reiss A, Moroishi T, Seguin L, Gomez G, Moo JS, Preynat-Seauve O, Krause KH, Chneiweiss H, Sarkaria JN, Guan KL, Dietrich PY, Weis SM, Mischel PS, Cheresh DA.

Cancer Cell. 2017 Dec 11;32(6):856-868.e5. doi: 10.1016/j.ccell.2017.10.016. Epub 2017 Nov 30.

11.

First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies.

Migliorini D, Mach N, Aguiar D, Vernet R, Landis BN, Becker M, McKee T, Dutoit V, Dietrich PY.

Oncoimmunology. 2017 Jun 21;6(8):e1338235. doi: 10.1080/2162402X.2017.1338235. eCollection 2017.

12.

[Brain tumor immunotherapy: Illusion or hope?]

Migliorini D, Dutoit V, Walker PR, Dietrich PY.

Bull Cancer. 2017 May;104(5):476-484. doi: 10.1016/j.bulcan.2017.01.014. Epub 2017 Mar 17. Review. French.

PMID:
28318492
13.

ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells.

Bassoy EY, Kasahara A, Chiusolo V, Jacquemin G, Boydell E, Zamorano S, Riccadonna C, Pellegatta S, Hulo N, Dutoit V, Derouazi M, Dietrich PY, Walker PR, Martinvalet D.

EMBO J. 2017 Jun 1;36(11):1493-1512. doi: 10.15252/embj.201695429. Epub 2017 Mar 10.

14.

Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?

Dutoit V, Migliorini D, Dietrich PY, Walker PR.

Front Oncol. 2016 Dec 7;6:256. doi: 10.3389/fonc.2016.00256. eCollection 2016. Review.

15.

Immunotherapy of Brain Tumors.

Dutoit V, Migliorini D, Walker PR, Dietrich PY.

Prog Tumor Res. 2015;42:11-21. doi: 10.1159/000436986. Epub 2015 Sep 4. Review.

PMID:
26376741
16.

Extrachromosomal driver mutations in glioblastoma and low-grade glioma.

Nikolaev S, Santoni F, Garieri M, Makrythanasis P, Falconnet E, Guipponi M, Vannier A, Radovanovic I, Bena F, Forestier F, Schaller K, Dutoit V, Clement-Schatlo V, Dietrich PY, Antonarakis SE.

Nat Commun. 2014 Dec 4;5:5690. doi: 10.1038/ncomms6690.

17.

Immunotherapy for glioma: from illusion to realistic prospects?

Dietrich PY, Dutoit V, Walker PR.

Am Soc Clin Oncol Educ Book. 2014:51-9. doi: 10.14694/EdBook_AM.2014.34.51. Review.

18.

Comprehensive metagenomic analysis of glioblastoma reveals absence of known virus despite antiviral-like type I interferon gene response.

Cosset É, Petty TJ, Dutoit V, Cordey S, Padioleau I, Otten-Hernandez P, Farinelli L, Kaiser L, Bruyère-Cerdan P, Tirefort D, Amar El-Dusouqui S, Nayernia Z, Krause KH, Zdobnov EM, Dietrich PY, Rigal E, Preynat-Seauve O.

Int J Cancer. 2014 Sep 15;135(6):1381-9. doi: 10.1002/ijc.28670. Epub 2014 May 8.

19.

The relationship between brain tumor cell invasion of engineered neural tissues and in vivo features of glioblastoma.

Nayernia Z, Turchi L, Cosset E, Peterson H, Dutoit V, Dietrich PY, Tirefort D, Chneiweiss H, Lobrinus JA, Krause KH, Virolle T, Preynat-Seauve O.

Biomaterials. 2013 Nov;34(33):8279-90. doi: 10.1016/j.biomaterials.2013.07.006. Epub 2013 Jul 27.

PMID:
23899445
20.

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).

Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Müller B, Schiess R, Wild PJ, Rüschoff JH, Thalmann G, Dietrich PY, Aebersold R, Klingbiel D, Gillessen S; Swiss Group for Clinical Cancer Research (SAKK).

Eur Urol. 2013 Jul;64(1):150-8. doi: 10.1016/j.eururo.2013.03.040. Epub 2013 Apr 6.

PMID:
23582881

Supplemental Content

Loading ...
Support Center